Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis.
Blood-based biomarkers for androgen receptor changes may eventually help predict which prostate cancer patients respond to specific therapies.
This PubMed record reports: Prospective biomarker-stratified studies are needed to determine whether ctDNA AR alterations predict differential benefit from specific therapies. The finding is retained for rapid triage and requires downstream evidence review before clinical interpretation.
What the study was
- Study design
- Meta-analysis
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Clinical genitourinary cancer
Why it surfaced
Retained because its meta-analysis evidence is relevant to Early cancer detection (liquid biopsy, ctDNA, cfDNA); scoring is conservative for the available metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.